

<b>Title of paper:</b>	22.23 Q1 GM Cancer Pathway Board Work Programmes updated 30.06.22
<b>Purpose of the paper:</b>	To share with the GM Cancer Board the 22.23 Q1 GM Cancer Pathway Boards' work programmes update
<b>Summary outline of main points / highlights / issues</b>	<ul style="list-style-type: none"> <li>• This paper with work programmes embedded follows up on the actions in the previous 2 Cancer Board papers: (i) '<i>GM Cancer Pathway Boards Update</i>', author Alison Armstrong, included in papers for 28/3/22 Cancer Board and (ii) '<i>GM Cancer Pathway Boards' Work Programmes 22.23 Update</i>' author Susan Todd, included in papers for 23/05/22 Cancer Board.</li> <li>• Sharing of updated work programmes quarterly</li> <li>• Monitoring of work programmes</li> </ul>
<b>Author of paper and contact details</b>	<p><b>Name:</b> Susan Todd  <b>Title:</b> Programme Director - Transformation, GM Cancer  <b>Email:</b> susan.todd7@nhs.net</p>



## 1. Work Programmes

- The work programmes are developed by each Pathway Board, the process being led by the Pathway Board clinical lead and pathway manager
- The work programmes all have the same format, with sections relating to NHSE Long Term Plan/planning guidance: Prevention, early diagnosis, treatment, performance, personalised care and follow up, reducing inequalities, patient experience and user involvement, research, education
- For 22.23, the work programmes will be monitored through the Pathway Boards, with progress updated and shared quarterly with the GM Cancer Senior Management Team, GM Cancer wider team, Cancer Board members, and key stakeholders
- Key successes, risks and issues will be presented regularly at the GM Cancer Programme Assurance Group. Additionally, if escalation is required urgently, this will be to the Senior Management Team by the pathway manager/clinical lead
- The work programmes are living documents and may be revised within the year in light of emerging priorities

## 2. Collated Pathway Board Work Programmes Q1 22.23 update embedded below:



22.23 Q1 GM Cancer  
Pathway Board Work